Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841359 · ClinicalTrials.gov registry record · Phase 4
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
A Phase 4 study, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT01841359: Completed Phase 4 study, sponsored by Joslin Diabetes Center.
NCT01841359 is a Phase 4 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01841359, a Phase 4 study, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.
Primary Outcome
Baseline and post-treatment with pramlintide mixed meal testing plasma glucose values, area under the curve (AUC), calculated with the trapezoidal method. Plasma glucose was measured at timepoints (minutes): -5 (baseline), 10 minutes, 20 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes.
Interventions
- DRUG Pramlintide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-02-02 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 4 |
What the finished NCT01841359 record still lists
NCT01841359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Pramlintide is the first listed.
NCT01841359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01841359 about?
NCT01841359 is a clinical study titled "Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery". The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.
What is the current status of trial NCT01841359?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2010-02-02. Estimated completion is 2022-02-08.
What interventions are being tested in trial NCT01841359?
The interventions under investigation include: Pramlintide (DRUG).
Who is sponsoring clinical trial NCT01841359?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01841359's enrollment target sits among peer trials
22 1731st of 2000 higher than 259 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI